[3H]MK-801 binding to NMDA glutamatergic receptors in Parkinson's disease and progressive supranuclear palsy
Identifieur interne : 000548 ( Istex/Curation ); précédent : 000547; suivant : 000549[3H]MK-801 binding to NMDA glutamatergic receptors in Parkinson's disease and progressive supranuclear palsy
Auteurs : Sophie Holemans [Belgique] ; France Javoy [France] ; Yves Agid [France] ; E. Christian Laterre [Belgique] ; Jean-Marie Maloteaux [Belgique]Source :
- Brain Research [ 0006-8993 ] ; 1991.
English descriptors
- KwdEn :
Abstract
The interactions existing between glutamatergic and dopaminergic systems, notably in the basal ganglia, suggest that glutamatergic antagonists may have therapeutic interest in extrapyramidal disorders characterized by impaired dopaminergic transmission. The binding of [3H]dizocilpine maleate (MK-801) to glutamate receptors of the N-methyl-d-aspartate (NMDA)-subtypes was characterized in temporal and frontal cortex, in hippocampus and in subcortical areas (caudate nucleus and putamen) from controls and patients with Parkinson's disease or progressive supranuclear palsy. The binding affinity (KD) and the maximal specific binding capacity (Bmax) of [3H]MK-801 were unchanged in all the cerebral regions studied in both disease. This indicates the existence of preserved NMDA glutamate receptors, which is required for potential therapeutic efficacy of specific antagonists.
Url:
DOI: 10.1016/0006-8993(91)91747-O
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000548
Links to Exploration step
ISTEX:E84A3C69F12B98A24C9A2D9AFD53ACE76817ACA4Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">[3H]MK-801 binding to NMDA glutamatergic receptors in Parkinson's disease and progressive supranuclear palsy</title><author><name sortKey="Holemans, Sophie" sort="Holemans, Sophie" uniqKey="Holemans S" first="Sophie" last="Holemans">Sophie Holemans</name><affiliation wicri:level="1"><mods:affiliation>Laboratoire de Neurochimie, Université Catholique de Louvain, Brussels Belgium</mods:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Laboratoire de Neurochimie, Université Catholique de Louvain</wicri:regionArea></affiliation></author><author><name sortKey="Javoy, France" sort="Javoy, France" uniqKey="Javoy F" first="France" last="Javoy">France Javoy</name><affiliation wicri:level="1"><mods:affiliation>Laboratoire de Médecine Expérimentale, INSERM U 289, CHU Pitié-Salpêtrière, Paris, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire de Médecine Expérimentale, INSERM U 289, CHU Pitié-Salpêtrière, Paris</wicri:regionArea></affiliation></author><author><name sortKey="Agid, Yves" sort="Agid, Yves" uniqKey="Agid Y" first="Yves" last="Agid">Yves Agid</name><affiliation wicri:level="1"><mods:affiliation>Laboratoire de Médecine Expérimentale, INSERM U 289, CHU Pitié-Salpêtrière, Paris, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire de Médecine Expérimentale, INSERM U 289, CHU Pitié-Salpêtrière, Paris</wicri:regionArea></affiliation></author><author><name sortKey="Laterre, E Christian" sort="Laterre, E Christian" uniqKey="Laterre E" first="E. Christian" last="Laterre">E. Christian Laterre</name><affiliation wicri:level="1"><mods:affiliation>Laboratoire de Neurochimie, Université Catholique de Louvain, Brussels Belgium</mods:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Laboratoire de Neurochimie, Université Catholique de Louvain</wicri:regionArea></affiliation></author><author><name sortKey="Maloteaux, Jean Marie" sort="Maloteaux, Jean Marie" uniqKey="Maloteaux J" first="Jean-Marie" last="Maloteaux">Jean-Marie Maloteaux</name><affiliation wicri:level="1"><mods:affiliation>Correspondence: J.-M. Maloteaux, Laboratoire de Neurochimie et Service de Neurologie (1352), Université Catholique de Louvain, Avenue Hippocrate, 10, B-1200 Brussels, Belgium.</mods:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Correspondence: J.-M. Maloteaux, Laboratoire de Neurochimie et Service de Neurologie (1352), Université Catholique de Louvain, Avenue Hippocrate, 10, B-1200 Brussels</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Laboratoire de Neurochimie, Université Catholique de Louvain, Brussels Belgium</mods:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Laboratoire de Neurochimie, Université Catholique de Louvain</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E84A3C69F12B98A24C9A2D9AFD53ACE76817ACA4</idno><date when="1991" year="1991">1991</date><idno type="doi">10.1016/0006-8993(91)91747-O</idno><idno type="url">https://api.istex.fr/document/E84A3C69F12B98A24C9A2D9AFD53ACE76817ACA4/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000548</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000548</idno><idno type="wicri:Area/Istex/Curation">000548</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">[3H]MK-801 binding to NMDA glutamatergic receptors in Parkinson's disease and progressive supranuclear palsy</title><author><name sortKey="Holemans, Sophie" sort="Holemans, Sophie" uniqKey="Holemans S" first="Sophie" last="Holemans">Sophie Holemans</name><affiliation wicri:level="1"><mods:affiliation>Laboratoire de Neurochimie, Université Catholique de Louvain, Brussels Belgium</mods:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Laboratoire de Neurochimie, Université Catholique de Louvain</wicri:regionArea></affiliation></author><author><name sortKey="Javoy, France" sort="Javoy, France" uniqKey="Javoy F" first="France" last="Javoy">France Javoy</name><affiliation wicri:level="1"><mods:affiliation>Laboratoire de Médecine Expérimentale, INSERM U 289, CHU Pitié-Salpêtrière, Paris, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire de Médecine Expérimentale, INSERM U 289, CHU Pitié-Salpêtrière, Paris</wicri:regionArea></affiliation></author><author><name sortKey="Agid, Yves" sort="Agid, Yves" uniqKey="Agid Y" first="Yves" last="Agid">Yves Agid</name><affiliation wicri:level="1"><mods:affiliation>Laboratoire de Médecine Expérimentale, INSERM U 289, CHU Pitié-Salpêtrière, Paris, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire de Médecine Expérimentale, INSERM U 289, CHU Pitié-Salpêtrière, Paris</wicri:regionArea></affiliation></author><author><name sortKey="Laterre, E Christian" sort="Laterre, E Christian" uniqKey="Laterre E" first="E. Christian" last="Laterre">E. Christian Laterre</name><affiliation wicri:level="1"><mods:affiliation>Laboratoire de Neurochimie, Université Catholique de Louvain, Brussels Belgium</mods:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Laboratoire de Neurochimie, Université Catholique de Louvain</wicri:regionArea></affiliation></author><author><name sortKey="Maloteaux, Jean Marie" sort="Maloteaux, Jean Marie" uniqKey="Maloteaux J" first="Jean-Marie" last="Maloteaux">Jean-Marie Maloteaux</name><affiliation wicri:level="1"><mods:affiliation>Correspondence: J.-M. Maloteaux, Laboratoire de Neurochimie et Service de Neurologie (1352), Université Catholique de Louvain, Avenue Hippocrate, 10, B-1200 Brussels, Belgium.</mods:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Correspondence: J.-M. Maloteaux, Laboratoire de Neurochimie et Service de Neurologie (1352), Université Catholique de Louvain, Avenue Hippocrate, 10, B-1200 Brussels</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Laboratoire de Neurochimie, Université Catholique de Louvain, Brussels Belgium</mods:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Laboratoire de Neurochimie, Université Catholique de Louvain</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Brain Research</title><title level="j" type="abbrev">BRES</title><idno type="ISSN">0006-8993</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1991">1991</date><biblScope unit="volume">565</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="154">154</biblScope><biblScope unit="page" to="157">157</biblScope></imprint><idno type="ISSN">0006-8993</idno></series><idno type="istex">E84A3C69F12B98A24C9A2D9AFD53ACE76817ACA4</idno><idno type="DOI">10.1016/0006-8993(91)91747-O</idno><idno type="PII">0006-8993(91)91747-O</idno><idno type="ArticleID">9191747O</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0006-8993</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Glutamate antagonist</term><term>Human brain</term><term>N-methyl-d-aspartate receptors</term><term>Parkinson's disease</term><term>Progressive supranuclear palsy</term><term>[3H]Dizocilpine maleate</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The interactions existing between glutamatergic and dopaminergic systems, notably in the basal ganglia, suggest that glutamatergic antagonists may have therapeutic interest in extrapyramidal disorders characterized by impaired dopaminergic transmission. The binding of [3H]dizocilpine maleate (MK-801) to glutamate receptors of the N-methyl-d-aspartate (NMDA)-subtypes was characterized in temporal and frontal cortex, in hippocampus and in subcortical areas (caudate nucleus and putamen) from controls and patients with Parkinson's disease or progressive supranuclear palsy. The binding affinity (KD) and the maximal specific binding capacity (Bmax) of [3H]MK-801 were unchanged in all the cerebral regions studied in both disease. This indicates the existence of preserved NMDA glutamate receptors, which is required for potential therapeutic efficacy of specific antagonists.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000548 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 000548 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:E84A3C69F12B98A24C9A2D9AFD53ACE76817ACA4
|texte= [3H]MK-801 binding to NMDA glutamatergic receptors in Parkinson's disease and progressive supranuclear palsy
}}
| This area was generated with Dilib version V0.6.29. |  |